

Journal of Clinical and Medical Reviews

Review Article

The Evolution of Respiratory Syncytial Virus (RSV) Epidemiology and Burden in UK Children Following the COVID-19 Pandemic from March 23, 2020 to July 30, 2025: A Systematic Literature Review

Dima Ayash¹, Feyera Gemedo^{1,2*}

¹Learna and University of Buckingham, UK ,

²Jimma University, Ethiopia.

***Corresponding Author:** Feyera Gemedo, Learna and University of Buckingham.

Received Date: 05 November 2025; **Accepted Date:** 30 November 2025; **Published Date:** 05 December 2025

Copyright: © 2025 Feyera Gemedo, this is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Respiratory Syncytial Virus (RSV) is a leading cause of paediatric lower respiratory tract infections. The COVID-19 pandemic and associated non-pharmaceutical interventions (NPIs) profoundly disrupted RSV epidemiology. This review synthesises evidence on changes in RSV epidemiology, seasonality, and burden in UK children under five. A systematic literature review was conducted following PRISMA guidelines. Databases (PubMed, EBSCO, Cochrane) and grey literature (UKHSA, NHS) were searched for studies (2010-2024). Data on incidence, hospitalisation, seasonality, and economic burden were extracted and synthesised narratively. Pre-pandemic, RSV exhibited predictable winter seasonality, causing ~30,000 annual hospitalisations. NPIs led to a near-elimination of RSV in 2020-21. This was followed by an intense off-season resurgence in summer 2021, with cases increasing by over 1,250%, severely straining paediatric services. The annual economic burden is substantial (~£80 million). New preventative strategies (maternal vaccination, monoclonal antibodies) show significant promise. The pandemic caused a fundamental shift in RSV epidemiology in the UK, validating the 'immunity debt' hypothesis. These findings underscore the need for adaptable surveillance and the equitable implementation of new immunisation strategies to mitigate the considerable clinical and economic burden of RSV.

Keywords: Respiratory Syncytial Virus, RSV, Paediatrics, United Kingdom, COVID-19, Epidemiology, Seasonality, Immunity Debt, Systematic Review.

Introduction

Respiratory Syncytial Virus (RSV) is the predominant cause of acute lower respiratory tract infections in infants globally [1]. In the UK, pre-pandemic RSV followed a consistent seasonal pattern (October-March), resulting in approximately 30,000 hospitalisations and 450,000 GP consultations annually in children [2,1]. The COVID-19 NPIs suppressed RSV circulation by over 99% in the 2020-21 season (Bardsley et al., 2022), creating an "immunity debt." The subsequent relaxation of measures triggered an unprecedented off-season resurgence in summer 2021 [3]. This period of disruption coincided with the advent of new preventative interventions,

including nirsevimab (a monoclonal antibody) and maternal vaccines [4,5].

This systematic review therefore aims to synthesise evidence to answer: How have the epidemiology, seasonal patterns, and burden of RSV in UK paediatric populations changed following the COVID-19 pandemic?

Methodology

A systematic literature review was conducted in accordance with PRISMA guidelines [6]. Searches of electronic databases

es (PubMed, EBSCOhost, Cochrane Library) and grey literature sources (UKHSA, NHS England) were performed for studies published between 2010 and 2024. Search strings combined terms such as ('Respiratory Syncytial Virus' OR RSV) AND (child*) AND ('United Kingdom' OR UK) AND (COVID-19) AND (epidemiology OR hospitalisation). Inclusion criteria focused on studies of children (<5 years) in the UK, reporting on RSV incidence, hospitalisation, seasonality, or burden. All study designs (e.g., observational studies, modelling, reports) were considered. Following duplicate removal, titles/abstracts were screened, and full texts of eligible studies were assessed. Data were extracted and synthesised narratively due to study heterogeneity.

Results

Study Selection

The search identified 6,250 records. After screening, 48 studies met the inclusion criteria (see PRISMA flow diagram, Appendix A).

Pre-Pandemic Epidemiology (Pre-2020)

RSV demonstrated predictable winter seasonality, resulting in an estimated 29,000-30,000 hospitalisations annually [1]. Infants under six months bore the greatest burden [10].

Pandemic Suppression (2020-2021)

NPIs led to a 99.5% reduction in laboratory-confirmed RSV cases and an 80.8% decrease in hospitalisations during the 2020-21 season [2].

Post-Pandemic Resurgence (2021-Onwards)

An intense, off-season surge occurred in summer 2021, with a 1,258% increase in cases and 7,604 excess hospital admissions [2]. While severity was comparable to pre-pandemic seasons, the timing placed unprecedented strain on services [7]. This prompted the accelerated adoption of new prevention strategies [8].

Economic Burden and Inequalities

The annual economic burden of RSV is estimated at £80 million [9]. Higher hospitalisation rates are observed in children from socioeconomically deprived backgrounds and certain ethnic minorities [2,10]. Modelling suggests universal immunisation with nirsevimab could be highly cost-effective [11,12].

Discussion

This review demonstrates the profound impact of the COVID-19 pandemic on RSV epidemiology in UK children. The key finding is the validation of the "immunity debt" hypothesis, where suppressed viral circulation led to a large susceptible population, fuelling the intense 2021 summer outbreak.

The significant economic burden and identified health inequalities necessitate an equity-focused approach to the rollout of new interventions like nirsevimab and maternal vaccination. While cost-effectiveness models are promising [11,13] their real-world applicability depends on uptake and the evolving seasonality of RSV. The link between severe infant RSV and subsequent asthma remains an area for further research [14]

Limitations: This review is subject to potential language bias and relies partly on modelling data. The rapidly evolving evidence base is a constraint.

Conclusion

The COVID-19 pandemic fundamentally altered the landscape of RSV in the UK, replacing predictable seasonality with a more volatile pattern. The clinical and economic burden remains high and inequitable. The new era of RSV immunisation offers a paradigm shift in prevention. Its success hinges on equitable implementation, robust surveillance, and ongoing research into the long-term effectiveness of interventions and the sequelae of RSV infection.

Recommendations

- **Research:** Conduct longitudinal studies on the RSV-asthma link and implementation research on new immunisation programmes.
- **Surveillance:** Enhance integrated systems to monitor RSV seasonality and intervention impact in real-time.
- **Policy:** Prioritise equitable delivery of maternal vaccines and nirsevimab to ensure all children benefit.

Acknowledgements

The author would like to recognize the support of Learna and the University of Buckingham. Special thanks and appreciation go to Dr. Feyera Gameda, Assoc. Prof, Scientist, MSc dissertation supervisor, for exceptional mentoring and observance throughout the project.

Appendices

Appendix A: PRISMA 2020 Flow Diagram

This diagram illustrates the process of identifying, screening, and selecting studies for inclusion in the systematic review. Figure 1: PRISMA 2020 Flow Diagram of the Study Selection Process.

Description of the Process

1. **Identification:** A systematic search of academic databases (e.g., PubMed, Cochrane Library) and grey literature sources yielded 6,250 records.
2. **Screening:** The titles and abstracts of all 6,250 records

were screened against the pre-defined inclusion and exclusion criteria. This led to the exclusion of 5,900 records that were not relevant.

3. **Eligibility:** The full text of the remaining 350 reports was retrieved and assessed in detail. A further 302 reports were excluded for reasons such as focusing on the

wrong population (e.g., adults), being conducted outside the UK, or being an ineligible study type (e.g., editorial).

4. **Included:** A total of 48 studies met all eligibility criteria and were included in the final systematic review for data extraction and synthesis.

Appendix B: Data Extraction Table (Sample of key studies provided below for context).

Study Author(s) & Year	Study Design	Key Findings
Bardsley et al. (2022)	Retrospective Observational	99.5% reduction in RSV (2020-21); 1,258% surge in summer 2021.
Taylor et al. (2016)	Modelling Study	Pre-pandemic baseline: ~30,000 annual hospitalisations.
Fusco et al. (2022)	Economic Analysis	Annual RSV burden: ~£80 million.
Fyles et al. (2023)	Cost-effectiveness Model	Nirsevimab is highly cost-effective, preventing ~16,000 hospitalisations.

Table B1: Data Extraction Summary (Sample)

Declaration

This research is conducted under the auspices of Learna and the University of Buckingham, UK. Reproduction or duplication by any other institution or individual is prohibited. This manuscript has not been published elsewhere, nor is it currently under consideration for publication in any other journal. All authors have reviewed and approved this submission.↵

References

1. Taylor, Sylvia, Robert J. Taylor, Roger L. Lustig, Cynthia Schuck-Paim, François Haguinet, David J. Webb, John Logie, Gonçalo Matias, and Douglas M. Fleming. "Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK." *BMJ open* 6, no. 6 (2016): e009337.
2. Bardsley, Megan, Roger A. Morbey, Helen E. Hughes, Charles R. Beck, Conall H. Watson, Hongxin Zhao, Joanna Ellis, Gillian E. Smith, and Alex J. Elliot. "Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study." *The Lancet Infectious Diseases* 23, no. 1 (2023): 56-66.
3. Abu-Raya, Bahaa, Marina Viñeta Paramo, Frederic Reichertz, and Pascal Michel Lavoie. "Why has the epidemiology of RSV changed during the COVID-19 pandemic?." *EClinicalMedicine* 61 (2023).

4. Department of Health & Social Care (2023) Respiratory syncytial virus (RSV) immunisation programme for infants and older adults: JCVI full statement, 11 September 2023. Available at: <https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023> (Accessed: 9 April 2025).
5. NHS England (2024) Maximising uptake of antenatal vaccinations and the introduction of a maternal vaccine against respiratory syncytial virus (RSV) for infant protection this autumn and winter: letter. Available at: <https://www.england.nhs.uk/long-read/maximising-uptake-of-antenatal-vaccinations-and-the-introduction-of-a-maternal-vaccine-against-respiratory-syncytial-virus-rsv-for-infant-protection-this-autumn-and-winter-letter/> (Accessed: 9 April 2025).
6. Page, Matthew J., Joanne E. McKenzie, Patrick M. Bossuyt, Isabelle Boutron, Tammy C. Hoffmann, Cynthia D. Mulrow, Larissa Shamseer et al. "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews." *bmj* 372 (2021).
7. Lumley, Sheila F., Nicholas Richens, Emily Lees, Jack Cregan, Elizabeth Kalimeris, Sarah Oakley, Marcus Morgan et al. "Changes in paediatric respiratory infections at a UK teaching hospital 2016–2021; impact of the SARS-CoV-2 pandemic." *Journal of Infection* 84, no. 1 (2022): 40-47.

8. UK Health Security Agency (2024) RSV vaccination of pregnant women for infant protection: information for healthcare practitioners. Available at: <https://www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals/rsv-vaccination-of-pregnant-women-for-infant-protection-information-for-healthcare-practitioners> (Accessed: 9 April 2025).
9. Fusco, F., Hocking, L., Stockwell, S., Bonsu, M., Fusco, Francesco, Lucy Hocking, Stephanie Stockwell, Margaretha Bonsu, Sonja Marjanovic, Stephen Morris, and Jon Sussex. "The burden of respiratory syncytial virus: understanding impacts on the NHS, society and economy." *Rand Health Quarterly* 10, no. 1 (2022): 2.
10. Reeves, R. M., P. Hardelid, R. Gilbert, Joanna Ellis, Hongxin Zhao, M. Donati, and Richard Pebody. "Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010–2014: the importance of birth month." *Epidemiology & Infection* 144, no. 10 (2016): 2049–2056.
11. Fyles, Fred, Helen Hill, Gregory Duncan, Emma Carter, Carla Solórzano, Kelly Davies, Lauren McLellan et al. "Surveillance towards preventing paediatric incidence of respiratory syncytial virus attributable respiratory tract infection in primary and secondary/tertiary healthcare settings in Merseyside, Cheshire and Bristol, UK." *BMJ Open Respiratory Research* 10, no. 1 (2023).
12. Kieffer, Alexia, Matthieu Beuvelet, Gerald Moncayo, Mersha Chetty, Aditya Sardesai, Robert Musci, and Richard Hudson. "Disease burden associated with all infants in their first RSV season in the UK: a static model of universal immunization with nirsevimab against RSV-related outcomes." *Infectious Diseases and Therapy* 13, no. 10 (2024): 2135–2153.
13. Hodgson, David, Neil Wilkins, Edwin van Leeuwen, Conall H. Watson, Jonathan Crofts, Stefan Flasche, Mark Jit, and Katherine E. Atkins. "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination." *The Lancet Regional Health—Europe* 38 (2024).
14. Driscoll, Amanda J., S. Hasan Arshad, Louis Bont, Steven M. Brunwasser, Thomas Cherian, Janet A. Englund, Deshayne B. Fell et al. "Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting." *Vaccine* 38, no. 11 (2020): 2435–2448.

Citation: Dima Ayash, Feyera Gameda, The Evolution of Respiratory Syncytial Virus (RSV) Epidemiology and Burden in UK Children Following the COVID-19 Pandemic from March 23, 2020 to July 30, 2025: A Systematic Literature Review. *J. Clin. Med. Rev.* Vol. 4 Iss. 2 (2025). DOI: 10.58489/2836-2330/026